OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
26 sept. 2024 06h00 HE
|
OMEICOS Therapeutics GmbH
Interim data confirms OMT-28’s strong safety profile in PMD patients, top-line data expected mid-2025 BERLIN, GERMANY, September 26, 2024 – OMEICOS, a biopharmaceutical company developing...